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Background: Pendred syndrome (PS) and nonsyndromic hearing loss associated with enlarged vestibular aqueduct
(EVA) are caused by SLC26A4 mutations. The Okinawa Islands are the southwestern-most islands of the Japanese
archipelago. And ancestral differences have been reported between people from Okinawa Island and those from
the main islands of Japan. To confirm the ethnic variation of the spectrum of SLC26A4 mutations, we investigated
the frequencies of SLC26A4 mutations and clinical manifestations of patients with EVA or PS living in the Okinawa
Islands.
Methods: We examined 22 patients with EVA or PS from 21 unrelated families in Okinawa Islands. The patient’s
clinical history, findings of physical and otoscopic examinations, hearing test, and computed tomography (CT) scan
of the temporal bones were recorded. To detect mutations, all 21 exons and the exon–intron junctions of SLC26A4
were sequenced for all subjects. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) for SLC26A4
and calculations using the comparative CT (2−ΔΔCT) method were used to determine the pathogenicity associated
with gene substitutions.
Results: SLC26A4 mutations were identified in 21 of the 22 patients. We found a compound heterozygous mutation
for IVS15 + 5G > A/H723R in nine patients (41%), a homozygous substitution of IVS15 + 5G > A in six patients (27%),
and homozygous mutation for H723R in five patients (23%). The most prevalent types of SLC26A4 alleles were
IVS15 + 5G > A and H723R, which both accounted for 15/22 (68%) of the patients. There were no significant
correlations between the types of SLC26A4 mutation and clinical manifestations. Based on qRT-PCR results,
expression of SLC26A4 was not identified in patients with the homozygous substitution of IVS15 + 5G > A.
Conclusions: The substitution of IVS15 + 5G > A in SLC26A4 was the most common mutation in uniquely found in
patients with PS and EVA in Okinawa Islands. This suggested that the spectrum of SLC26A4 mutation differed from
main islands of Japan and other East Asian countries. The substitution of IVS15 + 5G > A leads to a loss of SLC26A
expression and results in a phenotype of PS and EVA.* Correspondence: ganahaa@med.u-ryukyu.ac.jp
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Profound hearing loss affects about 1 in 300 to 1 in
1000 newborns [1-4], and about one-half of these cases
can be attributed to genetic factors [5]. About 51% of
these cases are due to single nucleotide polymorphisms
[5]. As to inheritance pattern among monogenic pro-
bands, about 1% is X-linked, 22% is autosomal domin-
ant, and 77% is autosomal recessive [5]. Pendred
syndrome (PS) is an autosomal recessive disorder char-
acterized by congenital sensorineural hearing loss and
goiter [6]. The causative gene for PS and EVA was iden-
tified to be SLC26A4 [7,8]. Enlarged vestibular aqueduct
(EVA) is a common inner ear malformation that can be
diagnosed radiographically in patients with impaired
hearing (Figure 1). EVA is frequently associated with PS
[9-11]. In addition to PS, SLC26A4 mutations also cause
nonsyndromic hearing loss with EVA in the absence of a
thyroid phenotype [12,13].
Previous studies revealed that the spectrum of
SLC26A4 mutations varied on the basis of ethnic back-
ground [14,15]. Tsukamoto et al. [15] demonstrated that
SLC26A4 mutations occurred in 90% of families with a
history of PS and in 78% of families with a history of
EVA in Japan. Among these SLC26A4 mutations, H723R
was suggested to have a founder effect in the Japanese
population.
The Okinawa Islands are the southwestern-most
islands of the Japanese archipelago (Figure 2). Previous
studies suggested that there were substantial ancestral
differences between Okinawa Islands the main islands of
Japan [16]. In this study, we examined patients with
EVA or PS from the Okinawa Islands to determine the
frequencies and the genotypes of SLC26A4 mutations
and their clinical manifestations.
Methods
Subjects
From May 2008 to July 2012, 22 patients (8 males, 14 fe-
males; age range: 0–33 years; mean age: 5.8 years; median
age: 8.5 years; Table 1) were diagnosed with PS or EVA in
the Department of Otorhinolaryngology, Head and Neck
Surgery of the University of the Ryukyus, Japan.Figure 1 Computed tomography of the temporal bone showing an e
The vestibular aqueduct is not identified in control subject (A). The enlargePrior to enrollment, all subjects provided a written
informed consent. Our research protocol was approved by
the Ethical Review Board of the University of the Ryukyus.
Clinical manifestations of PS and EVA
Clinical history of 22 patients with neuro-otologic symp-
toms was recorded. A physical examination, including
otoscopy, hearing level test, computed tomography (CT)
scan of the temporal bones, and examination for thyroid
goiter was conducted.
Depending on a subject’s ability, hearing level was de-
termined using auditory brainstem response, condi-
tioned orientated response, or pure tone audiogram.
Hearing level was defined as the average of the hearing
threshold at 0.5, 1.0, 2.0, and 4.0 kHz. Hearing was de-
scribed as: normal, < 20 dB; mild impairment, 21–40 dB;
moderate impairment, 41–70 dB; severe impairment,
71–90 dB; and profound impairment, >91 dB.
Neck palpation or echography of the neck was
performed in all patients, to determine thyroid goiter. In
addition, their serum levels of thyroid-stimulating hor-
mone (TSH) and free thyroxine (FT4) were measured to
evaluate thyroid function (normal values: 0.9–1.6 ng/dl
and 0.5–5.0 mU/l, respectively). A perchlorate test was
not performed.
High-resolution temporal bone CT was performed in
all patients to determine if there were any other inner
ear malformations in addition to EVA. EVA was defined
as a vestibular aqueduct with a diameter of >1.5 mm at
the midpoint between the common crus of the semicir-
cular canal and the external aperture of the vestibular
aqueduct on CT [17].
Mondini dysplasia was defined when the cochlea
consisted of 1.5 turns in which the middle and apical
turns had coalesced to form a cystic apex due to the ab-
sence of the interscalar septum [18,19].
Vestibular enlargement was defined when the ratio of
the membranous vestibule diameter to the inner ear
diameter of the lateral semicircular canal was >1.2 [20].
Vertigo was investigated based on spontaneous nystag-
mus, caloric vestibular test or patients’ self-reporting of
past episode. The spontaneous nystagmus was evaluatednlarged vestibular aqueduct. Circles show the vestibular aqueduct.
d vestibular aqueduct is identified in a patient with EVA (B).
Figure 2 Location of the Okinawa islands in relation to East Asia. The Okinawa islands are located between Taiwan and the Japanese island
of Kyushu. The Japanese archipelago comprises Hokkaido, Honshu, Kyusyu, and the Okinawa islands, as well as some smaller islands.
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Morita, Kyoto, Japan).
SLC26A4 genotyping
Genomic DNA was extracted from whole blood using a
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).
To detect mutations, all 21 exons and the exon–intron
junctions of SLC26A4 were sequenced for all subjects. A
35 step cycle of Polymerase chain reactions (PCR) was
performed as follows: initial denaturation at 94°C for
5 min; 35 cycles of 94°C for 40 s, 60°C for 40 s, and 72°C
for 1 min; and a final extension at 72°C for 5 min. PCR
reactions were run using a programmable thermal cycler
(Verti™ 96-Well Thermal Cycler, Applied Biosystems, CA,
USA).
PCR products were purified using a Wizard® SV Gel
and PCR Clean-Up System (Promega, WI, USA) and dir-
ectly sequenced using an ABI PRISM 3130 × l Genetic
Analyzer (Applied Biosystems). The sequences obtained
were aligned and compared using the BLAST program
with known human genome sequences available in the
GenBank database.
We surveyed the substitution IVS15 + 5G > A in 100
healthy objects as control.
The genotype of the IVS15 + 5G > A was detected by
digestion of the PCR product with the restriction en-
zyme SspI (New England Biolabs, Ipswich, MA, U.S.A).
Total RNA isolation and reverse-transcription
Total RNA was isolated from leukocytes using a
QIAamp RNA Blood Mini Kit (Qiagen) according to themanufacturer’s protocol. Before cDNA synthesis, residual
DNA was removed by incubation with RNase-free DNase
I (Ambion Inc., City, TX, USA). Then, total RNA was
reverse transcribed using a TaKaRa Prime Script High Fi-
delity RT® Kit (TaKaRa, Tokyo, Japan) according to the
manufacturer’s protocol. Possible contaminating genomic
DNA in RNA samples was determined by electrophoresis.Quantitative nested real-time PCR
Nested real-time quantitative (q) PCR was performed to
investigate the level of SLC26A4 expression in the blood.First-step PCR (conventional PCR)
A conventional PCR assay was performed in a 10 μl reac-
tion mixture that included 2 μl of cDNA, 0.5 units of DNA
Taq polymerase (TaKaRa), 2.5 mM deoxynucleotide tri-
phosphates (dNTPs), 1 μM forward and reverse primers
for first-step PCR (Table 2), 10 × buffer, and 1.875 mM
MgCl2, with distilled water (H2O) for the final reaction vol-
ume of 10 μl. A 33 step cycle of PCR were performed as
follows: 94°C for 5 min, 33 cycles of 94°C for 30 s, 60°C for
30 s, 72°C for 40 s, and a final extension at 72°C for 5 min.Second-step PCR (quantitative nested PCR)
Following the first PCR, a second PCR was performed
using a set of internal primers (Table 2). The reaction
mixture contained 1 μl of the first PCR product (diluted
10-fold), 10 μl of SYBR Premix Ex Taq, and 0.2 μM of
the internal forward and reverse primers; the final
Table 1 Summary of clinical features of 22 patients
Age (years) CT PTA Vertigo Thyroid
EVA MD VE HL (dB) Conductive hearing loss Goiter Thyroid function
1 3 R + + + SO unknown - - normal
L + + + SO unknown
2 14 R + + - 105 + - + normal
L + + - 96 +
3 21 R + + + 73 + + + normal
L + + + 91 +
4 21 R + - - 81 + + + normal
L + - - 85 +
5 28 R + + + 96 + + + normal
L + + + SO +
6 33 R + + - 101 + + + normal
L + + + 106 +
7 1 R + + - SO unknown - - normal
L + + + SO unknown
8 1 R + - - SO unknown - - normal
L + - - 103 unknown
9 2 R + + - 101 unknown - - normal
L + + - 100 unknown
10 12 R + - - 95 + - + normal
L + - - 100 +
11 29 R + + + 85 + - -
L + + + 110 +
12 0 R + - - 55 unknown + - normal
L + - - 73 unknown
13 3 R + - + 85 unknown + - normal
L + + + 58 +
14 5 R + + + 95 + + - normal
L + + + 93 +
15 5 R + + + 103 + - - normal
L + + + 100 unknown
16 6 R + - - 81 + + - normal
L + - - 91 +
17 7 R + - - 83 + - - normal
L + - + 81 +
18 14 R + + + 96 + - + normal
L + + + 91 +
19 16 R + - + 91 + - + normal
L - - + 21 -
20 26 R + - - 98 + + - normal
L + - + 103 +
21 5 R + + + 85 + - - normal
L + + - 97 +
22 10 R + - - 53 + - - normal
L - - - 15 -
EVA enlarged vestibular aqueduct, MD Mondini malformation, VE vestibular enlargement, PTA pure tone audiogram, HL hearing level, SO scale out, NA no
available data.
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Table 2 Primer sequences used for nested real-time PCR
Nested PCR assay Sequence PCR product size (bp)
First-step PCR (external primer) Exon 14 forward TCTTGGAATGGCCTTGGAAGC 282
Exon 17 reverse TGAAACAGCATCACTTATGATGC
Second-step PCR (internal primer) Exon 15 forward TGAAGAACCTCAAGGAGTGAAG 154
Exon 16 reverse TTTCTGTATTTTCCTCAGCGCT
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H2O. A Light Cycler real-time quantitative PCR system
(Roche, Basel Switzerland) was used for amplification
and detection of the PCR products. A 40 step cycle of
thermal cycler program was performed as follows: de-
naturation at 95°C for 5 min; 40 cycles of 95°C for 10 s,
60°C for 20 s, and 72°C for 40 s; followed by recording
the fluorescence values after each elongation step and
melting curve analysis with denaturation at 95°C for
5 s, annealing at 65°C for 1 min, and redenaturation by
increasing the temperature to 95°C. The second-step
PCR products were separated by 1.5% agarose gel elec-
trophoresis, stained with ethidium bromide, and visual-
ized by UV transillumination. For this analysis, we used
three control subjects with no mutations (wild type),
three patients compound heterozygous for IVS15 + 5G >
A/H723R, and three patients homozygous for IVS15 +
5G > A.Validation of comparative CT (2−ΔΔCT) method and
calculations for quantifying SLC26A4 mRNA
We used the CT (2−ΔΔCT) method by assuming approxi-
mately equal amplification efficiencies for both target
and reference genes. This prerequisite was verified by
performing a validation experiment using both SLC26A4
and a housekeeping gene. Calculations were made using
the comparative CT (2−ΔΔCT) method. GAPDH (glycer-
aldehyde 3-phosphate dehydrogenase), PGK-1 (phospho-
glycerate kinase 1), and ACTB (actin beta) were used as
internal reference genes for PCR normalization with re-
gard to the amount of RNA added to the reverse tran-
scription reactions. Normalized results were expressed
as the mean ratio of SLC26A4 mRNA to GAPDH mRNA,
PGK-1 mRNA, and ACTB mRNA. To evaluate relative
transcript levels, the threshold cycle value (Ct) of each
sample was used to calculate and compare the ΔCt of each
sample to that of the control subject and patients with a
compound heterozygous for IVS15 + 5G > A/H723R, and
a homozygous for IVS15 + 5G > A. ΔΔCT was also calcu-
lated to compare the transcript levels in the control sub-
ject, and patients with a compound heterozygous for
IVS15 + 5G > A/H723R, and a homozygous for IVS15 +
5G > A. The transcript levels were calculated in each
genotype with three subjects and each subject was calcu-
lated in triplicate.Results
Mutation analysis for SLC26A4
By direct DNA sequence analysis, SLC26A4 mutations
were observed in 21 of 22 patients. Among the 21 pa-
tients with mutations, a compound heterozygous muta-
tion for IVS15 + 5G > A/H723R was identified in nine
patients (Figure 3C, D), a homozygous mutation for
H723R was identified in five patients (Figure 3E), and a
homozygous substitution of IVS15 + 5G > A was identified
in six patients (Figure 3F). A compound heterozygous
substitutions for IVS15 + 5G > A/T527P was identified in
one subject. We could not identify any SLC26A4 muta-
tions in one subject (Table 3). We could not find the sub-
stitution IVS15 + 5G > A in 100 control objects.Clinical characteristics
Table 1 summarizes the clinical characteristics of all 22
subjects. High-resolution temporal bone CT scans re-
vealed that bilateral EVA was present in 20 patients and
unilateral EVA was present in other two. Mondini dys-
plasia and vestibular enlargement was observed in 17
ears (17/44; 39%) and 22 ears (22/44; 50%), respectively.
Hearing loss grades in the affected ears ranged from
moderate to profound in the patients with EVA (Table 1).
The hearing levels of the two unaffected ears were nor-
mal and mild hearing loss, respectively. Table 4 shows
the hearing level distributions based on genotypes. No
significant differences were expected in the distributions
for hearing level among the five genotype groups due to
the small sample of only 22 patients.
Neck examinations revealed thyroid goiters in 8 of 22
patients. Overall, 0% (0/11) and 73% (8/11) of the pa-
tients younger and older than 10 years of age, respect-
ively, had a thyroid goiter. Their serum FT4 and TSH
levels were within the normal ranges. There is no relation
between occurrence of goiter and mutation genotypes.SLC26A4 expression in patients with IVS15 + 5G > A
Electrophoretic separation of the real-time PCR products
did not exhibit any bands in patients with the homozygous
substitution for IVS15 + 5G > A (Figure 4C).
Because the SLC26A4 expression levels were not high
in blood samples, we investigated its expression using
nested real-time qPCR for three control subjects, three
Figure 3 Examples of direct sequence analysis of the SLC26A4 gene. Representative results of H723R and the IVS15 + 5G > A mutation
analysis are shown. Genomic sequences of the SLC26A4 gene in normal individuals (A), (B). A compound heterozygous mutation for IVS15 + 5G >
A/H723R (C), (D). A homozygous mutation for H723R (E). A homozygous substitution of IVS15 + 5G > A (F). The arrows indicate the
variant nucleotide.
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IVS15 + 5G > A/H723R, and three patients with the
homozygous substitution for IVS15 + 5G > A. The control
subjects had normal hearing without any malformations
of the inner or middle ear and no family history of hearing
loss. After obtaining a written informed consent, blood
samples were collected from each subject and were
subjected to Real-time PCR with SYBR Green and the
expression level was evaluated using the comparative CT
(2-ΔΔCT) method. The relative SLC26A4 expression levels
in the control no.1, control no.2 and control no.3 with no
SLC26A4 mutations were 9089 ± 441.5 (standard devi-
ation), 2417 ± 189.5, and 4956 ± 260.4 respectively. In
patient no.12, patient no.14 and patient no.16 with a com-
pound heterozygous mutation for IVS15 + 5G > A/H723R
were 979.5 ± 79.12, 2846 ± 206.5 and 1183 ± 33.93 respect-
ively. In patient no.1, patient no.2 and patient no.4 with a
homozygous substitution for IVS15 + 5G > A were 1.96 ×
10-4 ± 7.66 × 10-5, 5.76 × 10-5 ± 3.37 × 10-6 and 4.35 ×
10-5 ± 8.09 × 10-6 respectively (Figure 5).
Based on the results of both electrophoresis and RT-
nested qPCR, no SLC26A4 expression was observed in pa-
tients with homozygous substitution of IVS15 + 5G > A.Discussion
Correlations between SLC26A4 genotypes and hearing
phenotypes
Hearing loss in patients with EVA and PS is usually ap-
parent at the pre- or perilingual stage [6,21]. Hearing
loss in EVA and PS is sensorineural with some mixed
hearing loss in the low-frequency range [22-27]. The
hearing level sometimes deteriorates suddenly and may
be followed by a partial recovery, such as with fluctuat-
ing hearing loss [28,29]. In our study, hearing loss was
detected at the pre- or perilingual stage in all cases ex-
cept for two cases of unilateral EVA. However, in all
cases, hearing levels eventually deteriorated to severe or
profound loss (Table 1) and were permanent with or
without hearing fluctuation or stepwise hearing deterior-
ation. No significant differences were observed in the
hearing levels among the five genotypes (Table 4).
Correlations between SLC26A4 genotypes and thyroid
phenotype
SLC26A4 encodes for the 86 kDa transmembrane pro-
tein pendrin [7,30]. In the thyroid, this protein acts as
co-transporter of chloride and iodine in the thyroid







Sex Allele 1 Allele 2
1 0 3 M IVS15 + 5G > A IVS15 + 5G > A
2 2 14 F IVS15 + 5G > A IVS15 + 5G > A
3 3 21 F IVS15 + 5G > A IVS15 + 5G > A
4 2 22 F IVS15 + 5G > A IVS15 + 5G > A
5 0 23 M IVS15 + 5G > A IVS15 + 5G > A
6 0 29 F IVS15 + 5G > A IVS15 + 5G > A
7 0 1 F H723R H723R
8 1 1 F H723R H723R
9 4 2 M H723R H723R
10 0 12 F H723R H723R
11 5 29 M H723R H723R
12 0 0 M IVS15 + 5G > A H723R
13 2 3 M IVS15 + 5G > A H723R
14 0 5 F IVS15 + 5G > A H723R
15 1 5 F IVS15 + 5G > A H723R
16 0 6 F IVS15 + 5G > A H723R
17 2 7 F IVS15 + 5G > A H723R
18 2 14 F IVS15 + 5G > A H723R
19 7 16 F IVS15 + 5G > A H723R
20 5 26 M IVS15 + 5G > A H723R
21 1 5 M H723R T527P
22 7 10 F ND ND
ND not determined.
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reduced pendrin-induced chloride and iodide transport
and, ultimately, goiter [33].
Goiter usually develops around the end of the first
decade of life or during young adulthood, although the
time of onset and severity vary considerably among pa-
tients [12,34], and even within families [35]. Despite an
impaired incorporation of iodide, most patients with PS
are clinically and biochemically euthyroid [21,34,36].Table 4 Clinical features in different genotype groups
Genotype Hearin
Normal Mild Modera
IVS15 + 5 G > A homozygous (n = 6) 0 0 0
H723R homozygous (n = 5) 0 0 0
IVS15 + 5 G > A/H723R (n = 9) 0 1 2
IVS15 + 5G > /T527P (n = 1) 0 0 0
No mutation (n = 1) 1 0 1
Subtotal 1 1 3
Total 44
Normal: ≤20 dB; Mild: 21–40 dB; Moderate: 41–70 dB; Severe: 71–90 dB; Profound: >
MD Mondini malformation, VE Vestibular enlargement, CT computed tomography.To our knowledge, no previous studies have investi-
gated correlations between SLC26A4 genotypes and the
thyroid phenotype. In the present study, PS was diag-
nosed in 8 of 11 patients older than 10 years of age, but
not in any of the 11 patients who were younger than
10 years of age. This indicates that it is difficult to diag-
nose PS before the age of 10 years.
Thyroid function was normal in all of the 21 patients
we examined, as demonstrated by their normal serum
concentrations of FT4 and TSH. There were no signifi-
cant differences in serologic thyroid test results and goi-
ter status among patients with homozygous substitution
for IVS15 + 5G > A, the H723R homozygous mutation,
or compound heterozygous mutation for IVS15 + 5G >
A/H723R. Therefore, our results indicate that serologic
testing of FT4 and TSH levels is not useful to distinguish
between individuals with PS or EVA.Distributions of SLC26A4 mutations in EVA and PS
patients in Okinawa Islands
It was previously reported that the spectrum of SLC26A4
mutations varied based on ethnic background [35,36].
H723R and IVS7-2A > G are prevalent alleles that ac-
count for the majority of the observed SLC26A4 muta-
tions in East Asian populations [35]. In the Japanese
population, H723R was the most common mutation
[15,36,37]. In Chinese and Taiwanese populations, IVS7-
2A > G was the most common mutation [38-40], whereas
in the Korean population, H723R and IVS7-2A > G were
the most frequent and accounted for 60.2% (47/78) and
30.7% (24/78) of the mutated alleles, respectively [41].
Ancestral differences have been reported between
people from Okinawa Islands and those from the main
islands of Japan based on single-nucleotide polymorph-
ism genotypes [16]. We analyzed SLC26A4 mutations
among 22 patients with EVA or PS from 21 unrelated
families. H723R have been reported as the most com-
mon mutation found in the main islands of Japan. As
with H723R mutation, IVS15 + 5G > A substitution wasg level CT Vertigo
te Severe Profound MD VE
3 9 6/12 6/12 4/6
1 9 4/10 3/10 0/5
4 11 5/18 11/18 4/9
1 1 2/2 1/2 0/1
0 0 0/2 0/2 0/1
9 30 17/44 21/44 8/22
91 dB.
Figure 4 Expression of the SLC26A4 gene in patients with PS or
EVA. The expected RT-nested PCR amplification product of SLC26A4
was 154 base pairs (bp) in length. Agarose gel electrophoresis shows
the 154 bp band for the control subject (A) and the patient with
IVS15 + 5G > A/H723R compound heterozygous mutation (B);
however, there was no band for the patient with IVS15 + 5G > A
homozygous substitution (C).
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Okinawa patients. The substitution of IVS15 + 5G > A
in one allele have been reported only 10 cases in Asian
populations [36,42-45]. Thus, IVS15 + 5G > A was the
characteristic SLC26A4 gene mutation among patients
in Okinawa Islands, indicating a difference in the
spectrum of SLC26A4 mutations among patients in
Okinawa Islands compared with patients in otherFigure 5 Relative expression of the SLC26A4 gene in control
subjects and in patients with a homozygous mutation of IVS15 +
5G > A or compound heterozygous mutation of IVS15 + 5G >
A/H723R. The ratio of SLC26A4 mRNA to GAPDH mRNA is shown in
three control subjects (A, B, C), three patients with compound
heterozygous mutation of IVS15 + 5G > A/H723R (D, E, F), and three
patients with IVS15 + 5G > A homozygous substitution (G, H, I). No
expression of SLC26A4 was observed in the three patients with the
IVS15 + 5G > A homozygous substitution (G, H, I). All experiments
were done in tripricate.populations. These results suggest that this SLC26A4
mutation may have originated from a common ancestor.
Pathogenic effect of IVS15 + 5G > A substitution
The heterozygous substitution of IVS15 + 5G > A has
been assumed to cause aberrant splicing [36,42-45].
However, Yang et al. [42] could not find any abnormal
RT-PCR products related to the size for SLC26A4 se-
quence analysis in patients with splice mutation. Because
its pathogenicity was only implicated on the basis of un-
common polymorphisms, the pathogenic potential of
IVS15 + 5G > A still remains unknown.
Substitutions near the canonical splice sites are diffi-
cult to classify as pathogenic or non-disease causing.
Because such substitutions affect proper RNA splicing
but some substitutions do not cause any effect [46-48].
Thus, it is important to determine the pathogenic effect
of a particular substitution near the donor site by
mRNA analysis [48]. We investigated SLC26A4 expres-
sion in patients with compound heterozygous mutation
for IVS15 + 5G > A/H723R and homozygous substitu-
tion for IVS15 + 5G > A by RT-PCR and RT-real time
PCR by targeting genes around these mutations. No ab-
errant PCR products were detected in the patient with
heterozygous substitution of IVS15 + 5G > A (Figure 4B),
which suggests that IVS15 + 5G > A does not cause ab-
errant splicing, as also argued by Yang et al. However, in
patients with the homozygous substitution of IVS15 +
5G > A, SLC26A4 was not expressed, as shown in
Figure 4. In addition, for patients with the heterozygous
substitution, SLC26A4 expression was reduced from the
normal control level. These findings suggest that IVS15 +
5G > A disrupts pre-mRNA splicing and causes the loss of
SLC26A4 expression. The patients in Yang et al. [42] were
heterozyote so that Yang et al. [42] most likely amplified
the non-mutated allele. Taken together, our results
indicate that the substitution of IVS15 + 5G > A is a loss-
of-function mutation caused by a loss of SLC26A4
expression.
Conclusions
We found no correlations between the type of SLC26A4
mutation and hearing levels or the thyroid phenotype.
Moreover, thyroid testing using serum FT4 and TSH
levels was not useful for distinguishing between individ-
uals with PS and EVA.
The substitution of IVS15 + 5G > A in the SLC26A4
was unique and the most common in PS and EVA pa-
tients from Okinawa Islands. This supports that the
spectrum of SLC26A4 mutations differs by geographic
area in East Asia. Our qPCR results for SLC26A4 indi-
cate that the substitution of IVS15 + 5G > A should be a
pathogenic mutation that leads to a loss of SLC26A4 ex-
pression and results in a phenotype of PS and EVA.
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